Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR

N. Imahashi, R. Suzuki, T. Fukuda, K. Kakihana, H. Kanamori, T. Eto, Takehiko Mori, N. Kobayashi, K. Iwato, T. Sakura, K. Ikegame, Kurokawa M Kurokawa, T. Kondo, H. Iida, H. Sakamaki, J. Tanaka, K. Kawa, Y. Morishima, Y. Atsuta, Miyamura K Miyamura

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who received myeloablative allo-HCT in CR1. The 4-year OS for MSD (n=290) and matched unrelated donor (MUD; n=141) was 65% and 68% (P=0.50), respectively. In multivariate analysis, MUD had a similar risk of overall mortality as MSD (hazard ratio=0.90; 95% confidence interval, 0.62-1.30; P=0.58), whereas older age, female donor/male recipient (FDMR) combination, and requiring more than one course of induction chemotherapy to achieve CR1 were poor prognostic factors for OS. Thus, OS after MUD HCT with sex combinations other than FDMR was significantly higher than that after MSD HCT from female donors to male recipients (4-year OS 72% versus 55%, P=0.04). These results suggest that HCT, not only from MSD, but also from MUD, should be considered in younger patients with intermediate-risk AML in CR1, and that the donor-recipient sex combination is more important than the donor type in donor selection.

Original languageEnglish
Pages (from-to)56-62
Number of pages7
JournalBone Marrow Transplantation
Volume48
Issue number1
DOIs
Publication statusPublished - 2013 Jan

Fingerprint

Hematopoietic Stem Cell Transplantation
Cytogenetics
Tissue Donors
Siblings
Donor Selection
Unrelated Donors
Induction Chemotherapy
Multivariate Analysis
Confidence Intervals

Keywords

  • Allogeneic hematopoietic SCT
  • AML
  • First CR

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Imahashi, N., Suzuki, R., Fukuda, T., Kakihana, K., Kanamori, H., Eto, T., ... K Miyamura, M. (2013). Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. Bone Marrow Transplantation, 48(1), 56-62. https://doi.org/10.1038/bmt.2012.84

Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. / Imahashi, N.; Suzuki, R.; Fukuda, T.; Kakihana, K.; Kanamori, H.; Eto, T.; Mori, Takehiko; Kobayashi, N.; Iwato, K.; Sakura, T.; Ikegame, K.; M Kurokawa, Kurokawa; Kondo, T.; Iida, H.; Sakamaki, H.; Tanaka, J.; Kawa, K.; Morishima, Y.; Atsuta, Y.; K Miyamura, Miyamura.

In: Bone Marrow Transplantation, Vol. 48, No. 1, 01.2013, p. 56-62.

Research output: Contribution to journalArticle

Imahashi, N, Suzuki, R, Fukuda, T, Kakihana, K, Kanamori, H, Eto, T, Mori, T, Kobayashi, N, Iwato, K, Sakura, T, Ikegame, K, M Kurokawa, K, Kondo, T, Iida, H, Sakamaki, H, Tanaka, J, Kawa, K, Morishima, Y, Atsuta, Y & K Miyamura, M 2013, 'Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR', Bone Marrow Transplantation, vol. 48, no. 1, pp. 56-62. https://doi.org/10.1038/bmt.2012.84
Imahashi, N. ; Suzuki, R. ; Fukuda, T. ; Kakihana, K. ; Kanamori, H. ; Eto, T. ; Mori, Takehiko ; Kobayashi, N. ; Iwato, K. ; Sakura, T. ; Ikegame, K. ; M Kurokawa, Kurokawa ; Kondo, T. ; Iida, H. ; Sakamaki, H. ; Tanaka, J. ; Kawa, K. ; Morishima, Y. ; Atsuta, Y. ; K Miyamura, Miyamura. / Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR. In: Bone Marrow Transplantation. 2013 ; Vol. 48, No. 1. pp. 56-62.
@article{a078919f6b934886abddcd4b0373e54d,
title = "Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR",
abstract = "Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who received myeloablative allo-HCT in CR1. The 4-year OS for MSD (n=290) and matched unrelated donor (MUD; n=141) was 65{\%} and 68{\%} (P=0.50), respectively. In multivariate analysis, MUD had a similar risk of overall mortality as MSD (hazard ratio=0.90; 95{\%} confidence interval, 0.62-1.30; P=0.58), whereas older age, female donor/male recipient (FDMR) combination, and requiring more than one course of induction chemotherapy to achieve CR1 were poor prognostic factors for OS. Thus, OS after MUD HCT with sex combinations other than FDMR was significantly higher than that after MSD HCT from female donors to male recipients (4-year OS 72{\%} versus 55{\%}, P=0.04). These results suggest that HCT, not only from MSD, but also from MUD, should be considered in younger patients with intermediate-risk AML in CR1, and that the donor-recipient sex combination is more important than the donor type in donor selection.",
keywords = "Allogeneic hematopoietic SCT, AML, First CR",
author = "N. Imahashi and R. Suzuki and T. Fukuda and K. Kakihana and H. Kanamori and T. Eto and Takehiko Mori and N. Kobayashi and K. Iwato and T. Sakura and K. Ikegame and {M Kurokawa}, Kurokawa and T. Kondo and H. Iida and H. Sakamaki and J. Tanaka and K. Kawa and Y. Morishima and Y. Atsuta and {K Miyamura}, Miyamura",
year = "2013",
month = "1",
doi = "10.1038/bmt.2012.84",
language = "English",
volume = "48",
pages = "56--62",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR

AU - Imahashi, N.

AU - Suzuki, R.

AU - Fukuda, T.

AU - Kakihana, K.

AU - Kanamori, H.

AU - Eto, T.

AU - Mori, Takehiko

AU - Kobayashi, N.

AU - Iwato, K.

AU - Sakura, T.

AU - Ikegame, K.

AU - M Kurokawa, Kurokawa

AU - Kondo, T.

AU - Iida, H.

AU - Sakamaki, H.

AU - Tanaka, J.

AU - Kawa, K.

AU - Morishima, Y.

AU - Atsuta, Y.

AU - K Miyamura, Miyamura

PY - 2013/1

Y1 - 2013/1

N2 - Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who received myeloablative allo-HCT in CR1. The 4-year OS for MSD (n=290) and matched unrelated donor (MUD; n=141) was 65% and 68% (P=0.50), respectively. In multivariate analysis, MUD had a similar risk of overall mortality as MSD (hazard ratio=0.90; 95% confidence interval, 0.62-1.30; P=0.58), whereas older age, female donor/male recipient (FDMR) combination, and requiring more than one course of induction chemotherapy to achieve CR1 were poor prognostic factors for OS. Thus, OS after MUD HCT with sex combinations other than FDMR was significantly higher than that after MSD HCT from female donors to male recipients (4-year OS 72% versus 55%, P=0.04). These results suggest that HCT, not only from MSD, but also from MUD, should be considered in younger patients with intermediate-risk AML in CR1, and that the donor-recipient sex combination is more important than the donor type in donor selection.

AB - Allogeneic hematopoietic SCT (allo-HCT) from matched sibling donor (MSD) is recommended for younger patients with intermediate cytogenetic risk AML in first CR (CR1), whereas the role of alternative donor transplants in these patients is unknown. We retrospectively analyzed 605 patients with intermediate-risk AML, who received myeloablative allo-HCT in CR1. The 4-year OS for MSD (n=290) and matched unrelated donor (MUD; n=141) was 65% and 68% (P=0.50), respectively. In multivariate analysis, MUD had a similar risk of overall mortality as MSD (hazard ratio=0.90; 95% confidence interval, 0.62-1.30; P=0.58), whereas older age, female donor/male recipient (FDMR) combination, and requiring more than one course of induction chemotherapy to achieve CR1 were poor prognostic factors for OS. Thus, OS after MUD HCT with sex combinations other than FDMR was significantly higher than that after MSD HCT from female donors to male recipients (4-year OS 72% versus 55%, P=0.04). These results suggest that HCT, not only from MSD, but also from MUD, should be considered in younger patients with intermediate-risk AML in CR1, and that the donor-recipient sex combination is more important than the donor type in donor selection.

KW - Allogeneic hematopoietic SCT

KW - AML

KW - First CR

UR - http://www.scopus.com/inward/record.url?scp=84872123279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872123279&partnerID=8YFLogxK

U2 - 10.1038/bmt.2012.84

DO - 10.1038/bmt.2012.84

M3 - Article

VL - 48

SP - 56

EP - 62

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -